APA (7th ed.) Citation

Burger, J. A., Robak, T., Demirkan, F., Bairey, O., Moreno, C., Simpson, D., . . . Tedeschi, A. (2022). Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: Integrated analysis of two phase 3 studies. Leukemia & Lymphoma, 63(6), 1375. https://doi.org/10.1080/10428194.2021.2020779

Chicago Style (17th ed.) Citation

Burger, Jan A., et al. "Up to 6.5 Years (median 4 Years) of Follow-up of First-line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma and High-risk Genomic Features: Integrated Analysis of Two Phase 3 Studies." Leukemia & Lymphoma 63, no. 6 (2022): 1375. https://doi.org/10.1080/10428194.2021.2020779.

MLA (9th ed.) Citation

Burger, Jan A., et al. "Up to 6.5 Years (median 4 Years) of Follow-up of First-line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma and High-risk Genomic Features: Integrated Analysis of Two Phase 3 Studies." Leukemia & Lymphoma, vol. 63, no. 6, 2022, p. 1375, https://doi.org/10.1080/10428194.2021.2020779.